News & Insights

Cases & Deals

December 5, 2014

King & Spalding Advises Arbor Pharmaceuticals in Minority-Stake Sale to KKR

ATLANTA, December 5, 2014 – King & Spalding advised Arbor Pharmaceuticals in the sale of a minority stake in this privately held company to global investment firm KKR. The terms of the transaction were not disclosed.

The King & Spalding legal team was led by corporate partner Jack Capers(Atlanta) and partner-elect Matthew Stewart Silicon Valley), with assistance from the following lawyers:

Christopher Austin (associate, Atlanta)
Sawyer Duncan (associate, Atlanta)
Samira Hariramasamy (associate, Silicon Valley)
Nathan Mihalik (associate, Atlanta)
Brian Park (associate, Atlanta)
Daniel Ray (associate, Silicon Valley)
Spencer Stockdale (associate, Atlanta)

Intellectual property:
Rebecca Kaufman (partner, Atlanta)

John Sweet (partner, New York)

Kenneth Raskin (partner, New York)

Jeffrey Spigel (partner, Washington, D.C.)

FDA and life sciences:
Jessica Ringel (associate, Washington, D.C.)

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital and pediatric markets. 

About King & Spalding
Celebrating more than 125 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 800 lawyers in 17 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality and dedication to understanding the business and culture of its clients. More information is available at